OR WAIT null SECS
Through the partnership, Seven Bridges will centralize and manage terabytes of raw and processed scRNASeq data using its cloud-based bioinformatic analysis platform while working to expand Pfizer’s cloud platforms and capabilities.
Seven Bridges, a bioinformatics ecosystem provider, announced on Feb. 24, 2021 that it is supporting Pfizer’s development of a data management and collaboration solution for its single-cell ribonucleic acid sequencing (scRNASeq) data.
Under the terms of the partnership, Seven Bridges will centralize and manage terabytes of raw and processed scRNASeq data using its cloud-based bioinformatic analysis platform while working to expand Pfizer’s cloud platforms and capabilities, Seven Bridges said in a company press release.
"Interpreting large-scale, complex transcriptomics data is critically important for understanding the molecular and cellular basis of disease," said Enoch Huang, vice-president, Medicinal Sciences, Pfizer, in the press release. "We are confident that by working with the unique multi-cloud technology developed by Seven Bridges and by benefiting from the depth and breadth of their expertise in bioinformatics and cloud computing, their solution will assist us in maximizing the value of the data we generate."
"Seven Bridges believes that genomics—and single-cell RNA sequencing in particular—will continue to play an increasingly vital role in the discovery of novel drugs and vaccines," said Bill Moss, CEO, Seven Bridges, in the press release. "We are thrilled that Pfizer has chosen our platform to help the company address these unique data management needs. And we look forward to supporting the development of a scRNASeq data storage solution that meets Pfizer's research and development requirements."
Source: Seven Bridges